Cargando…

A Study Comparing Acute Toxicities of Cetuximab and Cisplatin in Patients Undergoing Definitive Chemoradiation With Intensity-Modulated Radiotherapy for Locally Advanced Carcinoma Head and Neck

Purpose To study the acute toxicities of weekly cetuximab used concurrently with intensity-modulated radiotherapy (IMRT) versus weekly cisplatin with concurrent IMRT in locoregionally advanced head and neck squamous cell carcinoma (HNSCC). Materials and methods Fifty eligible patients were randomly...

Descripción completa

Detalles Bibliográficos
Autores principales:	Venkateshulu, Shruthi, BR, Kiran Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2021
Materias:	Radiation Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375004/ https://www.ncbi.nlm.nih.gov/pubmed/34430119 http://dx.doi.org/10.7759/cureus.16505

Ejemplares similares

Primary chemoradiation with cisplatin versus cetuximab for locally advanced head and neck cancer: a retrospective cohort study
por: Jeong, Il Seok Daniel, et al.
Publicado: (2020)

Cetuximab and anemia prevention in head and neck cancer patients undergoing radiotherapy
por: Maahs, Lucas, et al.
Publicado: (2022)

Assessment of the Role of Gefitinib With Concurrent Chemoradiation in Locally Advanced Head and Neck Cancer
por: Prajapati, Raju, et al.
Publicado: (2022)

Definitive Radiotherapy for Locally Advanced Merkel Cell Carcinoma of the Head and Neck Region: A Case Report
por: Gortman, Aron
Publicado: (2019)

Sarcopenia and Treatment Toxicity in Older Adults Undergoing Chemoradiation for Head and Neck Cancer: Identifying Factors to Predict Frailty
por: Morse, Ryan T., et al.
Publicado: (2022)

Primary Concurrent Chemoradiation in Head and Neck Cancers with Weekly Cisplatin Chemotherapy: Analysis of Compliance, Toxicity and Survival
por: Iqbal, Muhammad Shahid, et al.
Publicado: (2016)

Evaluation of a nurse-led aftercare intervention for patients with head and neck cancer treated with radiotherapy and cisplatin or cetuximab
por: Braat, Cora, et al.
Publicado: (2022)

Effect of sorafenib on cisplatin-based chemoradiation in head and neck cancer cells
por: Möckelmann, Nikolaus, et al.
Publicado: (2016)

Development of an optimum photon beam model for head‐and‐neck intensity‐modulated radiotherapy
por: Webster, Gareth J, et al.
Publicado: (2007)

Randomized trial on acute toxicities of weekly vs three‐weekly cisplatin‐based chemoradiation in head and neck cancer
por: Ameri, Ahmad, et al.
Publicado: (2021)

Definitive Chemoradiation With Dose Escalation for Locally Advanced Gastric Cancer: Case Studies
por: Anthony, Michelle, et al.
Publicado: (2020)

Gastrointestinal Cancer Found in the Cervix With Unknown Primary Site and Treated With Definitive Chemoradiation
por: Albana, Jasen, et al.
Publicado: (2022)

Feasibility of Induction Docetaxel, Cisplatin, 5-Fluorouracil, Cetuximab (TPF-C) Followed by Concurrent Cetuximab Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
por: Charalambakis, Nikolaos, et al.
Publicado: (2013)

Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma: A meta-analysis
por: Tang, Wen-Hua, et al.
Publicado: (2020)

Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone: Analysis of the Austrian head and neck cancer registry of the AGMT
por: Magnes, Teresa, et al.
Publicado: (2021)

Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer
por: Sridharan, Vishwajith, et al.
Publicado: (2016)

Chemoradiation with Cisplatin vs. Carboplatin for Squamous Cell Carcinoma of the Head and Neck (SCCHN)
por: Rades, Dirk, et al.
Publicado: (2023)

The value of plasma hypoxia markers for predicting imaging-based hypoxia in patients with head-and-neck cancers undergoing definitive chemoradiation
por: Rühle, Alexander, et al.
Publicado: (2022)

Comparing high‐dose cisplatin with cisplatin‐based combination chemotherapy in definitive concurrent chemoradiation setting for locally advanced head and neck squamous cell carcinoma (LAHNSCC)
por: Furqan, Muhammad, et al.
Publicado: (2019)

Phase II trial of individualized/dynamic cisplatin regimens for definitive concurrent chemoradiation therapy in patients with head and neck squamous cell carcinoma
por: Ahn, Dongbin, et al.
Publicado: (2020)

Factors Predictive of Protracted Course of Radiation Therapy in Patients Treated with Definitive Chemoradiation for Cervical Cancer
por: Zaki, Mark, et al.
Publicado: (2016)

Recapitulating the Pharmacological Interactions of Cetuximab with Sunitinib and Cisplatin in Head and Neck Carcinoma Cells in vitro
por: Dib, Maria, et al.
Publicado: (2022)

Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients
por: Sridharan, Vishwajith, et al.
Publicado: (2016)

Initial experience of radiotherapy plus cetuximab for Japanese head and neck cancer patients
por: Kurokawa, Marie, et al.
Publicado: (2015)

The dogma of Cetuximab and Radiotherapy in head and neck cancer – A dawn to dusk journey
por: Krishnamurthy, Sapna, et al.
Publicado: (2022)

Utilization of custom electron bolus in head and neck radiotherapy
por: Kudchadker, R. J., et al.
Publicado: (2003)

Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck
por: Trieu, Vanessa, et al.
Publicado: (2018)

Intravenous fluids for pain management in head and neck cancer patients undergoing chemoradiation
por: Rivers, Charlotte I., et al.
Publicado: (2021)

Polymorphisms in DNA mismatch repair pathway genes predict toxicity and response to cisplatin chemoradiation in head and neck squamous cell carcinoma patients
por: Nogueira, Guilherme Augusto Silva, et al.
Publicado: (2018)

Radiotherapy plus cetuximab for locally advanced squamous cell head and neck cancer in patients with cisplatin-ineligible renal dysfunction: A retrospective study
por: Imai, Chiaki, et al.
Publicado: (2022)

Unilateral Cervical Polyneuropathies following Concurrent Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer
por: Elghouche, Alhasan, et al.
Publicado: (2016)

Clinical Outcomes of Spatially Fractionated GRID Radiotherapy in the Treatment of Bulky Tumors of the Head and Neck
por: Choi, J. Isabelle, et al.
Publicado: (2019)

Dosimetric impact of dental metallic crown on intensity‐modulated radiotherapy and volumetric‐modulated arc therapy for head and neck cancer
por: Kamomae, Takeshi, et al.
Publicado: (2016)

A Comparison of the Toxicities in Patients With Locally Advanced Head and Neck Cancers Treated With Concomitant Boost Radiotherapy Versus Conventional Chemoradiation
por: Sharma, Ritu, et al.
Publicado: (2023)

Early-onset dropped head syndrome after radiotherapy for head and neck cancer: dose constraints for neck extensor muscles
por: Inaba, Koji, et al.
Publicado: (2016)

Cisplatin-Based Chemotherapy versus Cetuximab in Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer Treatment
por: Hu, Ming-Hung, et al.
Publicado: (2014)

Cisplatin, Cetuximab, and Radiation in Locally Advanced Head and Neck Squamous Cell Cancer: A Retrospective Review
por: Peddi, Prakash, et al.
Publicado: (2015)

Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance
por: Iannelli, Federica, et al.
Publicado: (2020)

Significance of neutrophil to lymphocyte ratio as a predictor of outcome in head and neck cancer treated with definitive chemoradiation
por: Kaźmierska, Joanna, et al.
Publicado: (2023)

Error on the stopping power ratio of ERKODENT's mouthpiece for head and neck carbon ion radiotherapy treatment
por: Lee, Sung Hyun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_s243db31ktf1l55rl0cif5celh